Quick answer: The ROI of prior authorization automation for a mid-to-large nephrology group comes from three stacked effects: staff hours returned per authorization, revenue protected by preventing lapsed dialysis authorizations and avoidable denials, and faster time-to-therapy that reduces patient attrition. The labor line is the easiest to calculate and the least persuasive to a board; the protected-revenue line is harder to estimate and does most of the actual work in the business case.
Build the model before you take the demo
Vendors will hand you an ROI calculator. Build your own first, because the assumptions inside theirs are the whole argument and you won't be able to see them.
You need four numbers from your own operations, and none of them require software to collect:
- Monthly PA volume, split by type (recurring, lab-gated, step-therapy)
- Average staff minutes per authorization, measured rather than estimated — have a coordinator time twenty of them
- Loaded hourly cost of the staff doing the work, including benefits and overhead
- Denial rate, with denials categorized as administrative or clinical
The fourth is the one most practices skip and the one that matters most. Pull your last 100 denials and sort them by a single question: would different documentation have changed the outcome? If yes, administrative. If the payer disputed whether the therapy was appropriate for this patient, clinical. Automation moves the first category and not the second, so the split determines your ceiling.
For a sanity check against national data, the 2025 AMA Prior Authorization Physician Survey found practices average 40 prior authorizations per physician per week and spend 13 hours of physician and staff time on them, with 40% employing staff dedicated exclusively to PA work. If your measured numbers are wildly below that, measure again.
The labor line: what it's worth and what it isn't
The arithmetic is straightforward.
Monthly PA volume × minutes per PA × loaded hourly cost ÷ 60 = current monthly labor cost.
For a mid-to-large nephrology group running, say, 900 authorizations a month at 22 minutes each with a loaded cost of $32 an hour, that's roughly $10,500 a month, or $126,000 a year, spent assembling packets and sitting on hold.
Automation doesn't take that to zero. A realistic assumption is that it removes most of the assembly and submission time on the authorization types it's configured for, while exceptions, peer-to-peers, and unconfigured payers still consume staff time. Model 50–70% reduction on the configured slice rather than a blanket cut, and be explicit in your model about which slice you've configured.
National benchmarks support the direction. The 2024 CAQH Index put the provider cost of a manual prior authorization at roughly $10.97 per transaction against about $5.79 for a fully electronic one — not a total elimination, but close to half.
Here's the honest problem with the labor line: it's soft. Your CFO knows that "6 hours a week saved" does not produce 6 hours of anything unless someone decides what that person now does. Which is why the labor line should be the supporting argument, not the headline.
The protected-revenue line does the real work
This is the number that moves boards, and almost nobody calculates it.
Two components:
Avoidable denials. Take your monthly denial count, multiply by the share that's administrative, multiply by average claim value, then by the share you currently fail to recover on appeal. That last factor matters — a denial you eventually overturn still cost you rework and cash-flow timing, but the write-off is the clean loss.
Lapsed authorizations. This one is usually invisible in your data because lapsed-auth denials get coded generically as "no auth on file" and worked individually. Ask your billing lead to pull a quarter's worth and count them. In nephrology, where dialysis authorizations recur and Medicare Advantage plans are less generous about retroactive approval, this is often the single largest recoverable line — and the easiest to model, because the target is zero.
The reason this line beats the labor line in a board conversation is that it's revenue, not effort. "We wrote off $180,000 last year on authorizations that expired" is a sentence that ends the debate. "We'll save six hours a week" invites one.
Honey Health's prior authorization agent is built around this framing — treating authorizations as tracked objects with expiration dates rather than as one-off requests, on the theory that the expensive failure in nephrology is the lapse rather than the transaction.
The third effect: time-to-therapy and patient attrition
The softest of the three, and worth including with appropriate hedging rather than leaving out.
When authorization takes three weeks instead of four days, some patients don't wait. They go to a competing group, they defer therapy, or they disengage. In nephrology, where the relationship is long-term and the therapy is ongoing, losing a patient early in the CKD trajectory forfeits years of downstream revenue rather than a single visit.
The trouble is attribution. You can measure median time from order to authorization decision, and you can measure it before and after. You cannot cleanly prove that a specific patient left because of a delay. So model this one as a range, state the assumption explicitly, and don't let it carry the business case.
CMS-0057-F helps here in 2026 by putting deadlines on payer responses — 7 calendar days for standard decisions, 72 hours for expedited — but the rule governs the payer's clock, not yours. If a packet sits in your queue for a week before submission, the payer's improved turnaround doesn't reach the patient.
The counterweights an honest model includes
Leave these out and your CFO will find them, which is worse than putting them in yourself.
Implementation cost and time. Most implementations run 6 to 12 weeks, and the constraint is EHR integration and payer configuration rather than the software. Budget internal staff time for that period, because your PA coordinator is the one who has to encode payer knowledge.
Payer coverage gaps. Advertised coverage and configured coverage are different things. Ask every vendor for their configured rule set against your top ten payers by volume, and model savings only on the covered slice.
Ongoing maintenance. Payer criteria change. Ask how rule updates are handled, how you're notified, and whether that's included in the subscription.
The redeployment question. Savings show up as capacity, not as a smaller payroll. If your board expects a headcount reduction and you deliver redeployed capacity, you've missed the number you set even if the operation improved. Set the expectation as redeployment from the start — it's both more accurate and more defensible.
Which nephrology groups see the fastest payback
Payback timing varies more by practice shape than by vendor.
The groups that recover the investment fastest tend to share three traits:
- High Medicare Advantage mix. MA plans apply more utilization management and maintain more varied criteria, so there's more administrative failure to eliminate.
- In-house dialysis authorization management. If you're tracking recurring authorizations yourself rather than through a dialysis partner, the lapse risk is yours — and so is the recovery.
- A PA coordinator who is already the bottleneck. When one person holds the entire book and the queue backs up when they take vacation, the fragility itself is a cost, and automation addresses it directly.
Groups that see slower payback usually have low MA penetration, already-clean first-pass approval rates, or a payer mix that a given vendor hasn't configured. None of those means don't buy; they mean the case rests on turnaround time and resilience rather than on recovered revenue, and your model should say so.
Frequently Asked Questions
What payback period is realistic for prior authorization automation?
Most nephrology groups modeling honestly land somewhere in the 9-to-18-month range, driven mainly by how much of their denial volume is administrative and whether they're carrying lapsed-authorization write-offs. Groups with high Medicare Advantage mix and in-house dialysis authorization tracking tend toward the shorter end.
How do we price the vendor side of the model?
Pricing is usually per-authorization or per-provider per-month and rarely published. Ask for pricing at your actual volume, ask what's included versus what's an add-on, and ask specifically whether payer rule maintenance is bundled. Compare against your measured current cost, not against zero.
Should we count physician time in the ROI model?
Count it separately rather than folding it in. Physician hours have a much higher loaded cost, so blending them inflates the number and invites challenge. Model staff time as the primary line and note physician time recovered as a separate benefit, particularly since the AMA survey ties prior authorization to burnout for 94% of physicians.
What if our denial rate is already low?
Then the labor line and turnaround time carry your case, and the protected-revenue line won't. That's a legitimate reason to buy, but a weaker one — be honest about it in the model rather than inflating the denial assumption to make the math work.
How long should we baseline before implementing?
Ninety days is enough to smooth month-to-month variation without delaying the decision. Track first-pass approval rate, median time from order to decision, lapsed-authorization count, and denial categorization. Without a real baseline you'll have no defensible way to report results afterward.
Does automation reduce headcount?
Rarely, and you shouldn't build the model on it. What changes is what the role does — assembling packets and holding for payers gives way to working exceptions, peer-to-peer coordination, and payer relationships. Present that as capacity redeployed, which is both accurate and easier to defend twelve months later.
